EsoCap

Executive Summary

EsoCap AG is a Swiss biotech company pioneering a mucoadhesive film-based drug delivery platform for targeted treatment of esophageal diseases. Founded in 2016 and headquartered in Basel, the company addresses a critical unmet need: rapid transit of drugs through the esophagus limits local therapeutic efficacy. EsoCap's innovative technology enables prolonged contact time of therapeutic agents with the esophageal mucosa, potentially improving outcomes for conditions such as eosinophilic esophagitis, esophageal cancer, and motility disorders. By leveraging a thin, flexible film that adheres to the esophageal lining, the platform offers controlled release and localized action, reducing systemic side effects. As a private, early-stage company, EsoCap is advancing its lead program towards clinical validation and exploring partnership opportunities to accelerate development. The platform's versatility also positions it for licensing deals with pharmaceutical companies seeking to repurpose existing drugs for esophageal indications. With a strong intellectual property portfolio and a focus on a niche but high-need area, EsoCap is poised to become a key player in esophageal drug delivery.

Upcoming Catalysts (preview)

• Q4 2026Initiation of Phase 1 Clinical Trial for Lead Candidate60% success
• Q2 2027Strategic Partnership or Licensing Deal with Major Pharma40% success
• Q3 2026Completion of Series A or B Funding Round70% success